Lonigutamab ugodotin is under clinical development by Laboratoires Pierre Fabre and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lonigutamab ugodotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lonigutamab ugodotin overview
W-0101 is under development for the treatment of advanced or metastatic solid tumors preferentially squamous non-small cell lung cancer, larynx carcinoma, ER positive breast cancer and soft tissue sarcomas. The drug candidate comprises of cytotoxic compound conjugated to a monoclonal antibody. The therapeutic candidate is administered by intravenous route.
Laboratoires Pierre Fabre overview
Laboratoires Pierre Fabre (Pierre Fabre), a subsidiary of Pierre Fabre Foundation that develops products and solutions including health and beauty. Its comprehensive product portfolio comprises of a range of complementary products, from prescribed drugs to dermo-cosmetics, including over-the-counter drugs and natural health products. It’s products address the full spectrum of health care needs from pathologies such as cancer or topical dermatitis to rare diseases including pediatric hemangioma, family hygiene to skin, hair and scalp care; and from day-to-day illnesses. Pierre Fabre sells and markets its products under various brands, including Derma, Galenic Klorane, Avene, Ducray and Rene Furterer, among others. Pierre Fabre is headquartered in Paris, Ile-de-France, France.
For a complete picture of Lonigutamab ugodotin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
